Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Exp Eye Res ; 153: 79-89, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27720708

RESUMEN

Experimental autoimmune uveoretinitis (EAU) represents an experimental model for human endogenous uveitis, which is caused by Th1/Th17 cell-mediated inflammation. Natural killer T (NKT) cells recognize lipid antigens and produce large amounts of cytokines upon activation. To examine the role of NKT cells in the development of uveitis, EAU was elicited by immunization with a peptide from the human interphotoreceptor retinoid-binding protein (hIRBP1-20) in complete Freund's adjuvant and histopathology scores were evaluated in C57BL/6 (WT) and NKT cell-deficient mice. NKT cell-deficient mice developed more severe EAU pathology than WT mice. When WT mice were treated with ligands of the invariant subset of NKT cells (α-GalCer or RCAI-56), EAU was ameliorated in mice treated with RCAI-56 but not α-GalCer. IRBP-specific Th1/Th17 cytokines were reduced in RCAI-56-treated compared with vehicle-treated mice. Although the numbers of IRBP-specific T cells detected by hIRBP3-13/I-Ab tetramers in the spleen and the draining lymph node were the same for vehicle and RCAI-56 treatment groups, RORγt expression by tetramer-positive cells in RCAI-56-treated mice was lower than in control mice. Moreover, the eyes of RCAI-56-treated mice contained fewer IRBP-specific T cells compared with control mice. These results suggest that invariant NKT (iNKT) cells suppress the induction of Th17 cells and infiltration of IRBP-specific T cells into the eyes, thereby reducing ocular inflammation. However, in sharp contrast to the ameliorating effects of iNKT cell activation during the initiation phase of EAU, iNKT cell activation during the effector phase exacerbated disease pathology. Thus, we conclude that iNKT cells exhibit dual roles in the development of EAU.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Autoinmunidad , Células T Asesinas Naturales/inmunología , Retinitis/inmunología , Uveítis/inmunología , Animales , Enfermedades Autoinmunes/patología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Femenino , Citometría de Flujo , Humanos , Ratones , Ratones Endogámicos C57BL , Células T Asesinas Naturales/patología , Retinitis/metabolismo , Retinitis/patología , Uveítis/metabolismo , Uveítis/patología
2.
J Leukoc Biol ; 96(6): 1077-85, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25201803

RESUMEN

AGEs are permanently modified macromolecule derivatives that form through nonenzymatic glycation of amino groups of proteins. Glycer-AGEs are highly toxic and play an important role in the pathogenesis of chronic inflammatory diseases. However, the contribution of glycer-AGEs to the pathogenesis of uveitis is unclear. In this study, we measured serum levels of glycer-AGEs in 100 patients with endogenous uveitis (22 with HLA-B27-associated uveitis, 20 with VKH disease, 14 with Behçet's disease, and 44 with sarcoidosis) and 33 healthy volunteers. We then examined the effect of the AGE inhibitor in a mouse model of human endogenous uveitis (EAU) by continuous oral administration of pyridoxamine at 200 or 400 mg/kg/day. Regardless of the etiology, serum glycer-AGE levels were significantly higher in patients with uveitis than in healthy subjects. Treatment with 400 mg/kg pyridoxamine significantly reduced the clinical and histological severity of EAU and was accompanied by a significant decrease in serum and retinal glycer-AGE levels and suppression of translocation of NF-κB p65 into the nucleus of retinal cells. Serum glycer-AGE levels may therefore serve as a biomarker of human uveitis, as well as systemic inflammation, and may contribute to the progression of uveitis, including diabetic iritis, via the activation of NF-κB.


Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Piridoxamina/uso terapéutico , Retinitis/tratamiento farmacológico , Uveítis/tratamiento farmacológico , Administración Oral , Adulto , Secuencia de Aminoácidos , Animales , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/patología , Síndrome de Behçet/sangre , Síndrome de Behçet/complicaciones , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Proteínas del Ojo/inmunología , Proteínas del Ojo/metabolismo , Proteínas del Ojo/toxicidad , Femenino , Antígeno HLA-B27/inmunología , Humanos , Masculino , Ratones , Persona de Mediana Edad , Datos de Secuencia Molecular , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/toxicidad , Transporte de Proteínas/efectos de los fármacos , Piridoxamina/administración & dosificación , Piridoxamina/farmacología , Retina/metabolismo , Retinitis/sangre , Retinitis/etiología , Retinitis/patología , Proteínas de Unión al Retinol/inmunología , Proteínas de Unión al Retinol/toxicidad , Sarcoidosis/sangre , Sarcoidosis/complicaciones , Uveítis/sangre , Uveítis/etiología , Uveítis/patología , Síndrome Uveomeningoencefálico/sangre , Síndrome Uveomeningoencefálico/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA